Citations

Showing 10 of 108119 citations.

Abstract PO-059: Multifaceted approaches to engaging Black and Latinx populations: From bed to bedside
Otero, Jessica, Webb, Fern J. , Askins, Nissa, Behar‐Horenstein, Linda S. , Baez-Conde, Lourdes, Suther, Sandra , Reams, Renee, Stern, Mariana Carla

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-059-PO-059

10.1158/1538-7755.disp21-po-059 Get It

Abstract INTRODUCTION The Cancer Research Education and Engagement (CaRE2) Health Equity Center seeks to eliminate cancer disparities within Black and Latinx communities through research, training, education, and community engagement. The goal of this presentation is to share the unique model of community engagement that was implemented by the CaRE2 Center's Community Outreach Core (COC) during the COVID-19 pandemic. METHODS During the COVID-19 pandemic, the COC hosted community outreach events to address prostate and pancreatic cancer disparities. We overcame the challenges of COVID-19 by hosting these programs over Zoom, Facebook, and Twitter and allowing participants to interact and ask questions. The use of these platforms allowed us to develop and implement the innovative “bed to bedside” model, which allowed participants to gain a well-rounded understanding of the cancer process from cancer survivors, physicians, and researchers of color. The goal of these events were to 1) increase awareness of the importance of prostate and pancreatic cancer screening, 2) educate patients and community members about potential prostate and pancreatic cancer treatments, 3) raise awareness on prostate and pancreatic cancer research, and 4) address the causes and solutions to prostate and pancreatic cancer disparities in the Black and Latinx community. RESULT A total of 4 events were conducted between September and November of 2021, reaching a total of 30 persons directly and about 30 more through social media. At each event, evidence-based prostate cancer and pancreatic cancer education was disseminated. Of the attendees, 48% identified as Black or African American and 14% as Latino(x). Attendees were given the option to provide feedback and 90% of attendees agreed or strongly agreed that the presentations met their expectations. One benefit of conducting outreach activities via these platforms was the ability for more individuals to attend and the elimination of transportation barriers. Participants reported that attending virtually was easy to navigate and provided a suitable environment given the ongoing pandemic. Participants also reported that they enjoyed the “bed to bedside” model and shared that hearing from a survivor of color led to them feeling more comfortable in considering cancer screening. CONCLUSION The Care2 COC, in partnership with the community, is addressing disparities in the Black and Latinx population. One of the barriers that we had to overcome was continuing community outreach during the COVID-19 pandemic. The decision to provide health education outreach over social platforms, was essential to maintain our reach and impact. This allowed for the implementation of the “bed to bedside” model that included the different perspectives of care. We concluded that this model was effective and helped normalize the treatment process. We also concluded that outreach to the community should continue to provide cancer information via virtual formats especially as the COVID-19 related incidence and mortality begins to increase. Citation Format: Jessica Otero, Fern Webb, Folakemi Odedina, Nissa Askins, Linda Behar-Horenstein, Lourdes Baez-Conde, Mariana Stern, Sandra Suther, Renee Reams. Multifaceted approaches to engaging Black and Latinx populations: From bed to bedside [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-059.
Abstract PO-056: The ReTOOL training program for underrepresented minority students: Best practices for virtual training in midst of COVID-19
Fathi, Parisa , Allen, John M. , Askins, Nissa, Seymour, Brian W. P., Lyon, Debra , Wilkie, Diana J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-056-PO-056

10.1158/1538-7755.disp21-po-056 Get It

Abstract Background: The Research Training Opportunities for Outstanding Leaders (ReTOOL) Program is an NCI/NIH-funded program (R25CA214225) that focuses on increasing the representation of underserved minority (URM) scientists in biomedical research careers to diversify the cancer research workforce. In addition to didactic curriculum and mentoring, each trainee works with a research mentor who provides hands-on research training experiences during the summer. Responding to the COVID-19 pandemic, the ReTOOL Program was modified to be virtual for the 2020 program. Methods: In response to the COVID19 global pandemic, the ReTOOL program leadership and faculty mentors modified the program element: didactic classes, research training, mentorship, seminars and support networks. The introductory week's independent reading sessions and weekly research seminars remained unchanged, as they were already virtual. Results: 20 students participated in the ReTOOL 2020 program, which started on May 4 and ended on August 7. An online program agreement was created to set expectations about participation, weekly reporting form to ensure trainees met program requirements, and evaluations for continuous monitoring. Specific adjustments that were made included: (1) the one-week preparatory didactic classes were conducted online using Zoom; (2) all research training took place virtually. All wet-lab research-training activities were cancelled, with the 2020 faculty mentors primarily dry-lab scientists and scientists with expertise in secondary data analyses. All trainees worked remotely with dedicated computer/laptop with camera for Zoom video communications, internet and dedicated space for learning. There was access to online library resources through University of Florida (UF); (3) Mentorship was provided with increased frequency of meetings with faculty mentors, program staff and peers; (4) Weekly social event to foster relationships and peer networks. Trainees developed fun, lighthearted activities; and (5) Research showcase with oral presentations through Zoom and innovative use of Twitter for poster sessions. A critical missed opportunity for the trainees was visiting different graduate or professional programs at UF. To fill this gap, we provided funding for each trainee to visit UF later. An advantage of moving the program to a virtual platform was co-mentoring by international mentors in Africa, through the Prostate Cancer Transatlantic Consortium (CaPTC). Additionally, the Service Learning experiences took place virtually. Conclusion: The COVID19 pandemic created an unusual circumstance but we were able to overcome the challenges, which included Zoom fatigue, adjustment to different time zones, isolation and information fatigue. While the ReTOOL research-training program was different in 2020, we were still be able to provide a meaningful experience for the trainees. 2020 trainees submitted 7 conference abstracts and 6 publications. This includes a special series focused on the ReTOOL program projects soon to publish in ecancermedicalscience Journal. Citation Format: Parisa Fathi, Folakemi Odedina, John Allen, Debra Lyon, Diana Wilkie, Nissa Askins, Brian Seymour. The ReTOOL training program for underrepresented minority students: Best practices for virtual training in midst of COVID-19 [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-056.
Abstract PO-012: Demographic factors and rural residence history associated with smoking history
Reed, Tyra, Gordon, Destiny, Dyal, Brenda W. , Ezenwa, Miriam O. , Johnson‐Mallard, Versie, Odedina, Folakemi T., Yao, Yingwei , Powell-Roach, Keesha , Krieger, Janice L. , Wilkie, Diana J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-012-PO-012

10.1158/1538-7755.disp21-po-012 Get It

Abstract Purpose: Smoking rates are higher in rural regions compared to urban regions. Given the mobility within the United States, rural norms around tobacco use may persist even after individuals move to urban areas. Little research is available regarding the difference in smoking history by demographics and rural residence history. The purpose of the study was to examine the influence of age, race, gender, and rural residence history on smoking history. Methods: In a cross-sectional study, we surveyed 1,786 adults using two sampling approaches: representative panels and a community-engaged sample. Participants were asked to complete the Florida Health and Ancestry Study (FHAS) survey through a link or by the phone with a research assistant. The smoking history question asked whether participants had smoked 100 cigarettes in their lifetime (yes/no). The rural residence question asked participants to indicate (yes/no) whether they have lived in a rural or farming community, or on a farm. We examined associations of smoking history with demographic variables using the Chi-square test and logistic regression including as predictors age group (young=18-30, middle age=31-50, old=51+ years), gender, race, and rural living by gender. Results: Participants were mostly White (16% Black, 84% White), female (47% male) and with a mean age around 50 years (mean 47.9±17.5 years, ranged 18 to 91). 36% of the sample reported a history of rural residence, and 51% reported that they had not smoked 100 cigarettes in their lifetime. A larger proportion of males (61%) smoked at least 100 cigarettes compared to females (37%) (p<.001). A significantly larger proportion of White participants (50%) smoked at least 100 cigarettes in their lifetime than Black participants (39%) (p=.001). A larger proportion of participants who had lived in a rural place (53%) had smoked at least 100 cigarettes compared to those who had not lived in a rural place (46%) (p=.005). Difference in mean age for those with or without a history of smoking 100 cigarettes was not statistically significant in this sample (p=.12). Logistic regression analysis revealed that relative to the old age group, the young age group was less likely (p<.001) and the middle age group was more likely (p=.002) to have smoked 100 cigarettes. Males (p<.001) were more likely to have smoked 100 cigarettes than females. Rural residence was associated with smoking among females (p<.001) but not among males (p=.70). Adjusting for other predictors, the association with race was not statistically significant in this sample (p=.06). Conclusion: Findings that the age group 18-30 years is more likely to have avoided becoming smokers is encouraging but must be analyzed more thoroughly relative to possible use of e-cigarettes and other tobacco products. To reduce individuals becoming smokers, we recommend increased cancer control efforts targeted to males in general and to females with a rural residence history. Additional research is planned to examine additional smoking variables and compare them to national data. Citation Format: Tyra Reed, Destiny Gordon, Brenda W. Dyal, Keesha Powell-Roach, Miriam O. Ezenwa, Versie Johnson-Mallard, Janice L. Krieger, Folakemi T. Odedina, Yingwei Yao, Diana J. Wilkie. Demographic factors and rural residence history associated with smoking history [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-012.
Abstract IA-40: CDKN2A germline rare coding variants and risk of pancreatic cancer in minority populations
McWilliams, Robert R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: IA-40-IA-40

10.1158/1538-7755.disp21-ia-40 Get It

Abstract Performing genetic epidemiology studies in underrepresented populations is challenging, but is extremely important in order to understand how cancer impacts differing populations, This can then allow more tailored and nuanced management of persons at risk. Our group at Mayo Clinic encountered some interesting preliminary findings regarding CDKN2A, but given small numbers of subjects in our registry, we needed to partner with other collaborators to have enough statistical power to make sense of the findings and generate a publishable result. This talk will focus on the means of doing this, the importance of team-based science across centers, and future opportunities. Background: Pathogenic germline mutations in the CDKN2A tumor suppressor gene are rare and associated with highly penetrant familial melanoma and pancreatic cancer in non-Hispanic whites. WeTo date, the prevalence and impact of CDKN2A rare coding variants (RCV) in racial minority groups remain poorly characterized. We examined the role of CDKN2A RCVs on the risk of pancreatic cancer among minority subjects. Methods: We performed a case-control study of germline mutations in CDKN2A among patients with incident pancreatic cancer and controls, focused on underrepresented minority populations. We sequenced CDKN2A in 220 African American pancreatic cancer cases, 900 noncancer African American controls, and 183 Nigerian controls. RCV frequencies were determined for each group and compared with that of 1,537 Non-Hispanic White patients with pancreatic cancer. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for both a case–case comparison of RCV frequencies in African Americans versus Non-Hispanic Whites, and case–control comparison between AA cases versus noncancer AA controls plus Nigerian controls. Smaller sets of Hispanic and Native American cases and controls also were sequenced. Race/ethnicity categorization was from self-report. Results: One novel missense RCV and one novel frameshift RCV were found among AA patients: 400G>A and 258_278del. RCV carrier status was associated with increased risk of pancreatic cancer among AA cases (11/220; OR, 3.3; 95% CI, 1.5–7.1; P ¼ 0.004) compared with African American and Nigerian controls (17/1,083). Further, African American cases had higher frequency of RCVs: 5.0% (OR, 13.4;95%CI, 4.9–36.7; P < 0.001) compared with Non-Hispanic White cases (0.4%). Conclusions: CDKN2A RCVs are more common in African Americans than in Non-Hispanic White patients with pancreatic cancer and associated with moderately increased pancreatic cancer risk among African Americans. Citation Format: Robert McWilliams. CDKN2A germline rare coding variants and risk of pancreatic cancer in minority populations [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA-40.
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS
Katz, Jonathan, Cudkowicz, Merit , Genge, Angela , Oskarsson, Björn , Hains, Avis B., Galanter, Joshua , Burgess, Braydon L., Kerchner, Geoffrey A. , Yeh, Felix L. , Ghosh, Arundhati Sengupta, Cheeti, Sravanthi , Brooks, Logan , Honigberg, Lee , Couch, Jessica A. , Rothenberg, Michael E. , Brunstein, Flávia, Sharma, Khema R., Berg, Leonard van den , Glass, Jonathan D. , Glass, Jonathan D , Oskarsson, Björn , Cudkowicz, Merit E , Rothstein, Jeffrey D. , Chen, Chen , Cho, Yong‐Yeon , Brooks, Logan, Berry, James D.

Mayo Clinic

Annals of Clinical and Translational Neurology | January 11, 2022 | Volume: 9 | Issue: 1 | Pages: 50-66

10.1002/acn3.51491 | PMID 35014217 Get It

AbstractObjectiveDual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first‐in‐human study investigated safety, tolerability, and pharmacokinetics (PK) of oral GDC‐0134, a small‐molecule DLK inhibitor. Plasma neurofilament light chain (NFL) levels were explored in GDC‐0134‐treated ALS patients and DLK conditional knockout (cKO) mice.MethodsThe study included placebo‐controlled, single and multiple ascending‐dose (SAD; MAD) stages, and an open‐label safety expansion (OLE) with adaptive dosing for up to 48 weeks.ResultsForty‐nine patients were enrolled. GDC‐0134 (up to 1200 mg daily) was well tolerated in the SAD and MAD stages, with no serious adverse events (SAEs). In the OLE, three study drug‐related SAEs occurred: thrombocytopenia, dysesthesia (both Grade 3), and optic ischemic neuropathy (Grade 4); Grade ≤2 sensory neurological AEs led to dose reductions/discontinuations. GDC‐0134 exposure was dose‐proportional (median half‐life = 84 h). Patients showed GDC‐0134 exposure‐dependent plasma NFL elevations; DLK cKO mice also exhibited plasma NFL compared to wild‐type littermates.InterpretationThis trial characterized GDC‐0134 safety and PK, but no adequately tolerated dose was identified. NFL elevations in GDC‐0134‐treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on‐target drug effects. The safety profile of GDC‐0134 was considered unacceptable and led to discontinuation of further drug development for ALS. Further work is necessary to understand relationships between neuroprotective and potentially therapeutic effects of DLK knockout/inhibition and NFL changes in patients with ALS.
Coagulopathy following Crotaliπae snakebites in northeast Florida
Chang, Simone , Seegobin, Karan , Maharaj, Satish Stephen

Mayo Clinic

Blood Coagulation & Fibrinolysis | January 11, 2022 | Volume: 33 | Issue: 4 | Pages: 220-223

10.1097/mbc.0000000000001123 | PMID 35638394 Get It

Effects of Crotalinae envenomation vary by geographical areas and research into coagulopathy and effects of antivenom are needed to optimize management. This was a single-center retrospective review with testing on presentation and 4 h after; antivenom administration was noted and data analyzed overall and comparing envenomations. One hundred and nineteen snakebites evaluated with 59 identified as Crotalinae and half receiving antivenom. PT/aPTT was elevated in 20% of water moccasin/copperhead and 21% of rattlesnake bites. DIC-like syndrome occurred in 8% water moccasin/copperhead and 6% rattlesnake bites. Antivenom did not seem to correct PT or aPTT at 4 h follow-up in most cases. Thrombotic microangiopathy was not seen. Coagulopathy was prevalent affecting one in five patients in this cohort and does seem to persist at short interval follow-up, even in those receiving antivenom. We support guidelines recommending clinical monitoring and serial coagulation profiles in such cases. Blood Coagul Fibrinolysis 30:000 – 000 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 11, 2022 | Volume: 55 | Issue: 4 | Pages: 401-411

10.1111/apt.16753 | PMID 35014040 Get It

SummaryBackgroundEpithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut.AimsTo evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of GB004 in patients with active UC.MethodsThis double‐blind, placebo‐controlled study randomised patients 2:1 to receive an oral solution of GB004 120 mg or placebo once daily for 28 days. Eligible patients had a Robarts Histopathology Index score ≥4 with neutrophils in the epithelium, total Mayo Clinic score 3‐12, Mayo Clinic endoscopic subscore ≥1, and blood in the stool, despite treatment with 5‐aminosalicylates, corticosteroids or immunosuppressants.ResultsThirty‐four patients were randomised. GB004 120 mg for 28 days was generally well‐tolerated. Adverse events occurred in 27.3% (3/11) and 39.1% (9/23) of patients in the placebo and GB004 groups respectively. Nausea and dysgeusia were most commonly reported in the GB004 group (0% for placebo and 21.7% [5/23] and 13.0% [3/23] respectively for GB004). There were no treatment‐related serious adverse events or deaths. GB004 exhibited minimal accumulation, with higher colonic concentrations relative to plasma. Exploratory pharmacodynamic and efficacy analyses demonstrated GB004 target engagement and numerically higher proportions of patients achieving improvement in multiple measures of disease activity, respectively, at day 28 for GB004 compared to placebo.ConclusionResults from this phase 1b trial support evaluation of the full therapeutic potential of GB004 for the treatment of UC. A phase 2 study (NCT04556383) is ongoing. Clinicaltrials.gov NCT03860896.
Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study
Archambault, Alexi , Jeon, Jihyoun , Thomas, Minta , Harrison, Tabitha A. , Bishop, D. Timothy , Brenner, Hermann , Casey, Graham , Chan, Andrew T. , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Li, Li , Pai, Rish K. , Parfrey, Patrick S. , Rennert, Gad , Lee, Jeffrey K. , Slattery, Martha L. , Win, Aung Ko , Woods, Michael O. , Peterse, Elisabeth F.P. , Cao, Yin , Du, Mengmeng , Corley, Douglas A. , Peters, Ulrike , Song, Mingyang , Archambault, Alexi N , Harrison, Tabitha A , Bishop, D Timothy , Brenner, Hermann , Chan, Andrew T , Chang-Claude, Jenny , Figueiredo, Jane C , Gruber, Stephen B , Gunter, Marc J , Guo, Feng , Hoffmeister, Michael , Jenkins, Mark A , Marchand, Loïc Le , Moreno, Victor , Pai, R K , Rennert, Gad , Sakoda, Lori C , Song, Mingyang , Win, Aung K , Woods, Michael O , Murphy, Neil , Campbell, Peter T , Peterse, Elisabeth F P , Cao, Yin , Liang, Peter S , Hayes, Richard B , Jeon, Jihyoun , Lin, Yi , Jenkins, Mark A. , Keku, Temitope O , Marchand, Loı̈c Le , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Song, Mingyang , Murphy, Neil , Campbell, Peter T. , Su, Yu-Ru , Lansdorp‐Vogelaar, Iris , Zeleniuch‐Jacquotte, Anne , Liang, Peter S. , Hsu, Li , Hayes, Richard B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djac003 | PMID 35026030 Get It

AbstractBackgroundThe incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.MethodsRelying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve.ResultsIncreasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores.ConclusionsPersonal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes.
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase
Yadav, Yogesh , Dunagan, Kelly T., Khot, Rachita , Venkatesh, Sudhakar K. , Wegner, Craig D., Basu, Ananda , Carter, Rickey E. , Basu, Rita , Dunagan, Kelly, Basu, Ananda , Carter, Rickey, Basu, Rita , Carter, Rickey E , Venkatesh, Sudhakar K , Port, John D. , Galderisi, Alfonso , Cobelli, Claudio

Mayo Clinic

Diabetes, Obesity and Metabolism | January 11, 2022 | Volume: 24 | Issue: 5 | Pages: 881-890

10.1111/dom.14646 | PMID 35014156 Get It

Abstract Aim To evaluate whether short‐term treatment with a selective 11β‐Hydroxysteroid dehydrogenase‐1 (11β‐HSD1) inhibitor, AZD4017, would block hepatic cortisol production and thereby decrease hepatic fat in patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), with or without type 2 diabetes (T2D). Materials and Methods This was a randomized, double‐blind, placebo‐controlled, phase 2 study conducted at two sites. Key inclusion criteria were the presence of NAFLD or NASH on magnetic resonance imaging (MRI) or recent biopsy positive for NASH. Enrolled patients were randomly assigned (1:1) to AZD4017 or placebo for 12 weeks. Primary outcomes were between‐group differences in mean change from baseline to week 12 in liver fat fraction (LFF) and conversion of 13 C cortisone to 13 C cortisol in the liver. Results A total of 93 patients were randomized; 85 patients completed treatment. The mean (standard deviation [SD]) change in LFF was −0.667 (5.246) and 0.139 (4.323) in the AZD4017 and placebo groups ( P = 0.441). For patients with NASH and T2D, the mean (SD) change in LFF was significantly improved in the AZD4017 versus the placebo group (−1.087 [5.374] vs. 1.675 [3.318]; P = 0.033). Conversion of 13 C cortisone to 13 C cortisol was blocked in all patients in the AZD4017 group. There were no significant between‐group differences (AZD4017 vs. placebo) in changes in fibrosis, weight, levels of liver enzymes or lipids, or insulin sensitivity. Conclusion Although the study did not meet one of the primary outcomes, AZD4017 blocked the conversion of 13 C cortisone to 13 C cortisol in the liver in all patients who received the drug. In patients with NASH and T2D, AZD4017 improved liver steatosis versus placebo.
Boric acid transport activity of human aquaporins expressed in Xenopus oocytes
Ushio, Kazutaka , Watanabe, Érika Ohta , Nagashima, Ayumi , Furuta, Tadaomi , Imaizumi, Genki, Romero, Michael F. , Kato, Akira , Nagashima, Ayumi , Furuta, Tadaomi , Romero, Michael F , Kato, Akira , Ushio, Kazutaka , Kamiya, Takehiro , Fujiwara, Toru

Mayo Clinic

Physiological Reports | January 11, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.14814/phy2.15164 | PMID 35014212 Get It